Using MRI to predict chemotherapy response in children with retinoblastoma
Prediction of the Response Using Dynamic Contrast-enhanced Magnetic Resonance Imaging Before Intra-arterial Chemotherapy in Children With Retinoblastoma
This study is testing whether special MRI scans can help doctors predict how well children with retinoblastoma will respond to chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Sex | All |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild Research network |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Paris) |
| Trial ID | NCT03267459 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the use of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to identify prognostic factors that can predict how well children with retinoblastoma will respond to intra-arterial chemotherapy. Retinoblastoma is a common eye cancer in young children, and while treatment is generally effective, some patients experience early progression. By analyzing MRI results, the study aims to improve treatment outcomes by identifying which patients are likely to benefit from chemotherapy. The study focuses on children diagnosed with grade B to D retinoblastoma who are prescribed intra-arterial chemotherapy.
Who should consider this trial
Good fit: Ideal candidates for this study are children diagnosed with grade B to D retinoblastoma who are set to receive intra-arterial chemotherapy.
Not a fit: Patients with retinoblastoma grades outside of B to D or those not prescribed intra-arterial chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better treatment planning and outcomes for children with retinoblastoma by identifying those who are likely to respond well to chemotherapy.
How similar studies have performed: While the use of MRI in cancer treatment is established, this specific approach to predicting chemotherapy response in retinoblastoma is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * grade B to D retinoblastoma * prescription of intra arterial chemotherapy Exclusion Criteria: * none
Where this trial is running
Paris
- Fondation A De Rothschild — Paris, France (Recruiting)
Study contacts
- Principal investigator: Augustin Lecler, MD — Fondation OPH A de Rothschild
- Study coordinator: Laurence Salomon, MD PhD
- Email: lsalomon@for.paris
- Phone: 0148036431
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.